Catalyst Event
Tempus AI Inc (TEM) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/25/2026, 12:00:00 AM
Tempus AI announced a strategic collaboration with Daiichi Sankyo on March 25, 2026, to use its AI models for an antibody drug conjugate (ADC) program in oncology.
Korean Translation
템퍼스 AI, 2026년 3월 25일 다이이찌산쿄와 종양학 분야 항체-약물 접합체(ADC) 프로그램에 AI 모델을 활용하는 전략적 협력 발표함
Related Recent Events
Recursion Pharmaceauticals Inc (RXRX) · Earnings Release
First quarter 2026 earnings release is scheduled for May 11, 2026, with analysts forecasting an EPS of approximately -$0.25. This event is critical for monitoring cash burn, justifying a medium importance estimate (expected 5-10% impact), forecasted
5/11/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
As quarterly earnings are key volatility events for growth-stage AI companies, Tempus AI's Q1 2026 earnings release on May 5, 2026, is scheduled
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release is scheduled; medium importance is estimated based on expected >=5% price impact.
4/30/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q1 2026 earnings release on April 23, 2026, with low importance estimated as no market reaction has occurred yet, expected.
4/23/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-21 scheduled. Low importance is estimated due to the routine nature of the announcement scheduled.
4/21/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
FDA decision on oral weight-loss drug orforglipron is expected; high importance is estimated due to potential for >=10% price impact.
4/10/2026, 12:00:00 AM